We are live on ! Find out more
KTTAW icon

Pasithea Therapeutics Warrants
KTTAW

4 hedge funds and large institutions have $278K invested in Pasithea Therapeutics Warrants in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

52% less capital invested

Capital invested by funds: $579K → $278K (-$301K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
+$19.3K
2
UBS Group
UBS Group
Switzerland
+$191

Top Sellers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$170K – – –
KC
2
Kepos Capital
New York
$57K – – –
WAM
3
Warberg Asset Management
Illinois
$51K +$19.3K +80,988 +37%
HF
4
HRT Financial
New York
– -$4K -12,483 Closed
UBS Group
5
UBS Group
Switzerland
– +$191 +800 New

KTTAW Hedge Fund Activity: Q1 2022 in Review

4 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q1 2022, worth a combined $278K — down 52% from $579K a quarter earlier.

Fund positioning in KTTAW was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Warberg Asset Management, adding an estimated $19.3K. The largest seller was HRT Financial, exiting entirely with an estimated $4K sold.

  • 4 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $278K of Pasithea Therapeutics Warrants stock for Q1 2022, down 52% quarter-over-quarter.
  • 1 fund opened new Pasithea Therapeutics Warrants positions in Q1 2022 and 1 closed out, a net change of 0 holders.
  • The largest Pasithea Therapeutics Warrants buyer in Q1 2022 was Warberg Asset Management, an estimated $19.3K added.
  • The largest Pasithea Therapeutics Warrants seller in Q1 2022 was HRT Financial, an estimated $4K sold.

Based on aggregated 13F filings for Q1 2022.